Pharma R&D returns hit six-year low

Projected returns on investment in research and development (R&D) for the top 12 pharma companies have fallen to their lowest level in six years, reveals a new report from Deloitte’s Centre for Health Solutions.

The projections, which take into account the next 21 years, are down to just 3.7% this year, from a high of 10.1% in 2010, according to the researcher’s annual study, highlighting the increased risk involved in bringing a successful treatment to market.

"Our analysis shows that the current model is not sustainable"